UIH(SH:688271) 光大证券研究·2025-06-27 14:02Group 1 - The company has announced a restricted stock incentive plan for 2025, granting 5 million shares at a price of 95 yuan per share to 1,368 individuals, representing 0.61% of the total share capital at the time of the announcement [2] - The incentive plan's assessment period is set from 2025 to 2027, with revenue growth targets of 20.00%, 44.00%, and 72.80% for the respective years, based on the 2024 revenue as a baseline [3] - The expected amortization expenses for the stock incentive plan from 2025 to 2028 are projected to be 57.34 million, 87.30 million, 44.76 million, and 14.80 million yuan respectively [3] Group 2 - The company has invested 2.261 billion yuan in R&D in 2024, accounting for 21.95% of its revenue, indicating a strong commitment to innovation [4] - The company has launched several strategic innovative products, including the uLinacHalosTx precision radiotherapy system and the uMR Max 3.0T MRI, which are expected to enhance its competitive position [4] - The domestic medical imaging equipment bidding market is projected to grow by 100.36% year-on-year from January to May 2025, suggesting a potential improvement in the company's performance as the market recovers [4]